Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053196 · ClinicalTrials.gov registry record · Phase 2
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
A Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 12
- Study locations
NCT00053196 is a Phase 2 study of Multiple Myeloma and Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 82 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT00053196, a Phase 2 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 12
- Study locations
Study Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapy after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor bone marrow or peripheral stem cell transplant works in treating patients with relapsed hematologic cancer after treatment with chemotherapy and autologous stem cell transplant.
Conditions Studied
Interventions
- BIOLOGICAL G-CSF
- DRUG fludarabine phosphate
- DRUG methotrexate
- DRUG busulfan
- BIOLOGICAL anti-thymocyte globulin
Study Locations (12)
Delaware
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
- St. Francis Hospital - Wilmington
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
Maryland
- Union Hospital Cancer Center at Union Hospital - Elkton MD
Missouri
- Siteman Cancer Center at Barnes-Jewish Hospital - St Louis
New Jersey
- Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees - Voorhees Township
New York
- Roswell Park Cancer Institute - Buffalo
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2002-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053196
The ClinicalTrials.gov registry entry for NCT00053196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which G-CSF is the first listed.
NCT00053196 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Delaware, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00053196 about?
NCT00053196 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replac...
What is the current status of trial NCT00053196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2002-12. Estimated completion is 2010-08.
What conditions does trial NCT00053196 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT00053196?
The interventions under investigation include: G-CSF (BIOLOGICAL), fludarabine phosphate (DRUG), methotrexate (DRUG), busulfan (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053196?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00053196 being conducted?
This trial has 12 study locations across California, Delaware, Maryland, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.